Efficacy Evaluation of Meloxicam 15mg Tablet through Bioequivalence Study in Indonesian Healthy Volunteers
Journal Title: Open Access Journal of Pharmaceutical Research - Year 2024, Vol 8, Issue 1
Abstract
Objective: The objective of this study is to compare the efficacy between the generic drug of Meloxicam 15mg Tablets produced by PT. Kimia Farma Tbk and its comparator (Movi-Cox® 15mg Tablet by PT. Boehringer Ingelheim Indonesia) by a study of bioequivalence in Indonesian healthy volunteers Methods: A randomized, single-dose, open-label, crossover two-way (2 treatments, 2 periods, and 2 sequences) under fasting condition were conducted in healthy Indonesian volunteers to evaluate bioequivalence between 2 formulations of Meloxicam 15mg tablet. This study required washout period of at least 7-days. The test and comparator drug were administered to subjects as a single oral dose. Blood samples were collected adequately (0–72 h) with 18 points to determine meloxicam concentrations in plasma using a validated LC-MS/MS analytical method. The number of subjects who participated and completed the study were 18 volunteer (9 male and 9 female). The pharmacokinetic parameters calculated in this study are AUC0-72, AUC0-inf, Cmax, tmax, and t½. The bioequivalence acceptance limit of 90% confidence interval (CI) with α = 5.00% is 80.00–125.00% for AUC and Cmax parameters. The estimation of Tmax and T½ in the bioequivalence study was based on a nonparametric statistical procedure on the original data using Wilcoxon Sign Test. Result: The results for AUC0-72 and Cmax were 108.07% (104.88-111.35) % and 105.24% (97.72-113.34) % respectively with intra-subject variability (%CV) was 5.15% for AUC0-t and 12.80% for Cmax. These results were within the regulatory acceptance limit 80.00-125.00%. Conclusion: Based on this result, it was concluded that the test formulation is bioequivalent to comparator formulation.
Authors and Affiliations
Priyanto*, Widiastuti E, Wahyono BH, Susilo MJ, Yunica NT, Bachtiar LNW, Anindyani SA, Azzaera AH and Wahyuningsih R
Keywords
Related Articles
- EP ID EP751874
- DOI 10.23880/oajpr-16000304
- Views 3
- Downloads 0
The LC-MS and GC-MS Based Isotopic Abundance Ratio Analysis of the Consciousness Energy Healing Treated Silver Sulfadiazine
Silver sulfadiazine is a topical antibiotic helps to prevent and treat wound infections in patients with severe burns. This research was performed to evaluate the impact of the Trivedi Effect®- Consciousness Energy Heal...
Aegle Marmelos (L.) Correa, A Potential Source for the Treatment of Diabetes Associated Alzheimer’s Disease: A Review
Alzheimer’s disease is a chronic neurodegenerative disorder leading to memory loss, which is caused by progressive wasting away of brain cells. Memory loss leads to changes in a person’s behavior, thinking and social ski...
Immunomodulatory Аspects and Mechanisms of Аction of βGlucans
β-glucans are found in bacterial and fungal cell walls and have been implicated in the initiation of anti-microbial immune response. β-glucansact on Dectin-1, complement receptor (CR3) and TLR-2/6 immune receptors. They...
Facile Synthesis of Copper Sulphide Nanoparticles using Trichoderma Herzlianism and Antibacterial Efficiency Enhancement by Gentamicin Sulfate
The application of biosynthesized semiconductor nanomaterials has gained recent attention towards pathogenic bacteria. This study reports cost- effective, eco- friendly biosynthesis of copper sulphide nanoparticles (CuS...
Carbohydrates Test and In Vitro Inhibitory Activities of AlphaGlucosidase and Alpha-Amylase of Stem Bark Extracts of Musanga Cecropioides
Elevated postprandial hyperglycemia is one of the risk factors linked to diabetes. Decreasing postprandial hyperglycemia is possible by inhibiting certain carbohydrate hydrolyzing enzymes like α-amylase and α-glucosidase...